Key regulatory hurdles cleared for Apogee's merger with AbbVie, with HSR, German, and Austrian approvals secured ahead of the August 11 vote
APGE has more than doubled off its 52-week low of $34.34.
Summary
Apogee's merger with AbbVie cleared U.S., German, and Austrian antitrust reviews, leaving only Australian clearance outstanding ahead of the August 11 stockholder vote.
Key Events · M&A and Partnerships · APGE
-
HSR Waiting Period Expired
A key closing condition for the AbbVie acquisition was satisfied when the U.S. antitrust waiting period under the HSR Act expired on August 5, 2026.
-
German and Austrian Clearances Obtained
Two more regulatory conditions were met: German FCO unconditional clearance was received on July 27, 2026, and the Austrian Cartel Act Phase 1 review period expired on August 4, 2026.
-
Australian ACCC Review Remains
The last identified regulatory hurdle is the Australian ACCC Phase 1 review, which expires on September 7, 2026, unless terminated earlier.
-
Stockholder Vote Set for August 11
The special meeting to approve the $135.11 per share all-cash merger remains scheduled for August 11, 2026, with the deal price near the current stock price.
Analysis · APGE · Life Sciences
The AbbVie acquisition of Apogee for $135.11 per share in cash has cleared three major regulatory conditions—U.S. HSR, German FCO, and Austrian Cartel Act—removing significant closing risk. The only remaining identified regulatory item is the Australian ACCC review, which has a Phase 1 deadline of September 7, 2026. With the stockholder vote set for August 11 and the deal price at a negligible discount to the current $134.27, these approvals materially de-risk the transaction and increase the likelihood of a timely close.
How filings like this one have moved
In the 30 days to Sep 18, 2026, 35.6% of the 1155 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.41%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, APGE was trading at $134.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.2B. The 52-week trading range was $34.34 to $134.46. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.